Akebia Therapeutics shares surge 16.62% intraday due to strong Q4 financial results and projected growth in Vafseovadadustat sales.

Akebia Therapeutics surged 16.62% intraday, driven by its Q4 2025 financial results showing $57.62 million in revenue (up 23.9% YoY, exceeding estimates of $48.37 million) and a narrowed net loss of -$12.24 million vs. -$22.8 million in 2024. The company also reported 2025 full-year revenue of $236.2 million (up 47% YoY) and projected significant 2026 growth for its product Vafseovadadustat, supported by expanded dialysis patient coverage (290,000 patients), new patient additions, and improved adherence. Pipeline advancements include ongoing phase II trials for praliciguat and planned phase II trials for AKB-097 in 2026.